Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo

International Journal of Oncology

Volumn 31, Issue 5, 2007, Pages 1087-1095

  Iwado, Eiji ^a   Daido, Shigeru ^a   Kondo, Yasuko ^a   Kondo, Seiji ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

2 5A antisense; Apoptosis; Glioma; Telomerase

Indexed keywords

2',5' OLIGOADENYLIC ACID; 2',5'-OLIGOADENYLATE; ADENINE NUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; DACARBAZINE; DRUG DERIVATIVE; HTR RNA; OLIGORIBONUCLEOTIDE; TELOMERASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ANIMAL; APOPTOSIS; ARTICLE; ASTROCYTE; AUTOPHAGY; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; GENE THERAPY; GENETICS; GLIOMA; HUMAN; METHODOLOGY; MOUSE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR CELL LINE;

ADENINE NUCLEOTIDES; ANIMALS; APOPTOSIS; ASTROCYTES; AUTOPHAGY; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GENE THERAPY; GLIOMA; HUMANS; MICE; OLIGONUCLEOTIDES, ANTISENSE; OLIGORIBONUCLEOTIDES; RNA, UNTRANSLATED; TELOMERASE;

EID: 38449091201     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Reardon DA, Rich JN, Friedman HS and Bigner DD: Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24: 1253-1265, 2006.
2. Van den Bent MJ, Hegi ME and Stupp R: Recent developments in the use of hemotherapy in brain tumours. Eur J Cancer 42: 582-588, 2006.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, and National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
4. Blackburn EH: Structure and function of telomeres. Nature 350: 569-573, 1991.
5. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB and Bacchetti S: Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11: 1921-1929, 1992.
6. De Lange T: Activation of telomerase in a human tumor. Proc Natl Acad Sci USA 91: 2882-2885, 1994.
7. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cell lines and cancer. Science 266: 2011-2015, 1994.
8. Broccoli D, Young JW and De Lange T: Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 92: 9082-9086, 1995.
9. Komata T, Kanzawa T, Kondo Y and Kondo S: Telomerase as a therapeutic target for malignant gliomas. Oncogene 21: 656-663, 2002.
10. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR and Royds JA: Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361: 836-838, 2003.
11. Ostenfeld T, Caldwell MA, Prowse KR, Linskens MH, Jauniaux E and Svendsen CN: Human neural precursor cells express low levels of telomerase in vitro and show diminishing cell proliferation with extensive axonal outgrowth following transplantation. Exp Neurol 164: 215-226, 2000.
12. Maran A, Maitra RK, Kumar A, Dong B, Xiao W, Li G, Williams BRG, Torrence PF and Silverman RH: Blockage of NF-B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 265: 789-792, 1994.
13. Cirino NM, Li G, Xiao W, Torrence PF and Silverman RH: Targeting RNA decay in respiratory syncytial virus infected cells with 2′- >5′oligoadenylate-antisense. Proc Natl Acad Sci USA 94: 1937-1942, 1997.
14. Maran A, Waller CF, Paranjape JM, Li G, Xiao W, Zhang K, Kalaycio ME, Maitra RK, Lichtin AE, Brugger W, Torrence PF and Silverman RH: 2′,5′-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells. Blood 92: 4336-4343, 1998.
15. Kondo S, Kondo Y, Li G, Silverman RH and Cowell JK: Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16: 3323-3330, 1998.
16. Mukai S, Kondo Y, Koga S, Komata T, Barna BP and Kondo S: 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res 60: 4461-4467, 2000.
17. Yatabe N, Kyo S, Kondo S, Kanaya T, Wang Z, Maida Y, Takakura M, Nakamura M, Tanaka M and Inoue M: 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther 9: 624-630, 2002.
18. Kondo Y, Koga S, Komata T and Kondo S: Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene 19: 2205-2211, 2000.
19. Koga S, Kondo Y, Komata T and Kondo S: Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther 8: 654-658, 2000.
20. Kushner DM, Paranjape JM, Bandyopadhyay B, Cramer H, Leaman DW, Kennedy AW, Silverman RH and Cowell JK: 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol 76: 183-192, 2000.
21. Komata T, Kondo Y, Koga S, Ko SC, Chung LWK and Kondo S: Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. Gene Ther 7: 2071-2079, 2000.
22. Kondo Y, Komata T and Kondo S: Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int J Oncol 18: 1287-1292, 2001.
23. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS and Pieper RO: Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 61: 4956-4960, 2001.
24. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19: 5720-5728, 2000.
25. Daido S, Kanzawa T, Yamamoto A, Takeuchi H, Kondo Y and Kondo S: Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. Cancer Res 64: 4286-4293, 2004.
26. Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB and Kondo S: Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phospha-tidylinositol 3-phosphate kinase/protein kinase B Inhibitors. Cancer Res 65: 3336-3346, 2005.
27. Faraoni I, Turriziani M, Masci G, De Vecchis L, Shay JW, Bonmassar E and Graziani G: Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin Cancer Res 3: 579-585, 1997.
28. Chou WC, Hawkins AL, Barrett JF, Griffin CA and Dang CV: Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest 108: 1541-1547, 2001.
29. Lin Z, Lim S, Viani MA, Sapp M and Lim MS: Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents. Am J Pathol 159: 711-719, 2001. (Pubitemid 32751101)
30. Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo S and Kondo S: Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br J Cancer 89: 922-929, 2003.
31. Kondo Y and Kondo S: Autophagy and cancer therapy. Autophagy 2: 85-90, 2006.
32. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y and Kondo S: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11: 448-457, 2004. (Pubitemid 38489422)
33. Ito H, Daido S, Kanzawa T, Kondo S and Kondo Y: Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. Int J Oncol 26: 1401-1410, 2005.
34. Kondo Y, Kanzawa T, Sawaya R and Kondo S: Role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5: 726-734, 2005.
35. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW and Villeponteau B: The RNA component of human telomerase. Science 269: 1236-1241, 1995.
36. Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, Arruda I and Robinson MO: A mammalian telomerase-associated protein. Science 275: 973-977, 1997.
37. Nakayama J, Saito M, Nakamura H, Matsuura A and Ishikawa F: TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell 88: 875-884, 1997.
38. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidpoff ML, Liu Q, Bacchetti S, Haber DA and Weinberg RA: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795, 1997.
39. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB and Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959, 1997.
40. Holt SE, Aisner DL, Baur J, Tesmer VM, Dy M, Ouellette M, Trager JB, Morin GB, Toft DO, Shay JW, Wright WE and White MA: Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 13: 817-826, 1999.
41. Mitchell JR, Wood E and Collins K: A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402: 551-555, 1999.
42. Kondo S, Tanaka Y, Kondo Y, Hitomi M, Barnett GH, Ishizaka Y, Liu J, Haqqi T, Nishiyama A, Villeponteau B, Cowell JK and Barna BP: Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J 12: 801-811, 1998.
43. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JHM, Meyerson M and Weinberg RA: Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5: 1164-1170, 1999.
44. Zhang X, Mar V, Zhou W, Harrington L and Robinson MO: Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Gene Dev 13: 2388-2399, 1999.
45. Mergny JL and Helene C: G-quadruplex DNA: a target for drug design. Nat Med 4: 1366-1367, 1998.